Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Joni, Saeid Sadeghi; Cheshmavar, Masoumeh; Shoureshi, Pouria; Zamani, Zohreh; Taoosi, Niusha; Akbari, Morteza; Afzali, Mahdieh

Joni, Saeid Sadeghi; Cheshmavar, Masoumeh; Shoureshi, Pouria; Zamani, Zohreh; Taoosi, Niusha; Akbari, Morteza; Afzali, Mahdieh.

Afiliação

Joni SS; Department of Radiology, Razi Hospital, Guilan University of Medical Sciences Rasht, Iran.
Cheshmavar M; Department of Neurology, Isfahan University of Medical Sciences Isfahan, Iran.
Shoureshi P; Department of Internal Medicine, Orange Park Medical Center Florida, USA.
Zamani Z; Department of Neurology, Firoozgar Hospital, Iran University of Medical Sciences Tehran, Iran.
Taoosi N; Islamic University of Riau Riau, Indonesia.
Akbari M; School of Medicine, Isfahan University of Medical Sciences Isfahan, Iran.
Afzali M; Department of Neurology, Isfahan University of Medical Sciences Isfahan, Iran.

Int J Physiol Pathophysiol Pharmacol ; 12(3): 88-94, 2020.

Article em En | MEDLINE | ID: mdl-32714497

Palavras-chave

Multiple sclerosis; fingolimod; liver enzymes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Int J Physiol Pathophysiol Pharmacol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google